Talnetant GlaxoSmithKline

Current Opinion in Investigational Drugs

Volumn 6, Issue 7, 2005, Pages 717-721

  Evangelista, Stefano ^a  

^a Menarini Richerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OSANETANT; PROLACTIN; RISPERIDONE; SB 213786; SB 218791; TACHYKININ RECEPTOR; TALNETANT; TESTOSTERONE;

BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; IN VITRO STUDY; IN VIVO STUDY; IRRITABLE COLON; NONHUMAN; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; URINE INCONTINENCE; WEIGHT GAIN;

ANIMALS; CLINICAL TRIALS, PHASE II; HUMANS; IRRITABLE BOWEL SYNDROME; MOLECULAR STRUCTURE; QUINOLINES; RECEPTORS, TACHYKININ; SCHIZOPHRENIA; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 21344449714     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. 121896 Tachykinin receptors and tachykinin receptor antagonists. Maggi CA, Patacchini R, Rovero P, Giachetti A J AUTON PHARMACOL 1993 13 1 23-93
2. 254987 SB Development Pipeline. SmithKline Beecham plc COMPANY WORLD WIDE WEB SITE 1997 April 13
3. 258069 Neurokinin-3 receptor antagonists. Giardina AM, Raveglia LF EXPERT OPIN THER PAT 1997 7 4 307-323
4. 263012 Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DW J PHARMACOL EXP THER 1997 281 3 1303-1311
5. 321679 Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. Identification of (S)- N-(1-phenylpropyl) -3-hydroxy-2-phenylquinoline-4-carboxamide (SB-223412). Giardina GAM, Raveglia LF, Grugni M, Sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttmann M, Cavagnera S et al J MED CHEM 1999 42 6 1053-1065
6. 328072 Annual Report 1998 - SmithKline Beecham. SmithKline Beecham plc ANNUAL REPORT 1998 December 31
7. 381682 Role of neurokinin 3 receptors on responses to colorectal distension in the rat: Electrophysiological and behavioral studies. Julia V, Su X, Bueno L, Gebhart GF GASTROENTEROLOGY 1999 116 5 1124-1131
8. 407558 Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. Bannon MJ, Brownschidle LA, Tian Y, Whitty CJ, Poosh MS, D'sa C, Moody CA BRAIN RES 1995 695 1 19-24
9. 3 receptor. Sarau HM, Feild JA, Ames RS, Foley JJ, Nuthulaganti P, Schmidt DB, Buckley PT, Elshourbagy NA, Brawner ME, Luttmann MA, Gardoma GA, Hay DW EUR J PHARMACOL 2001 413 2-3 143-150
10. 3 receptors in laboratory animals. Massi M, Panocka I, de Caro G PEPTIDES 2000 21 1 1597-1609
11. 446952 American Chemical Society - 23rd National Meeting (Part V) - Overnight Report, Orlando, FL, USA. Kibble A IDDB MEETING REPORT 2002 April 07-11
12. 446957 Research & Development: Product Pipeline. GlaxoSmithKline plc COMPANY WORLDWIDE WEBSITE 2002 March 28
13. 467734 Product development pipeline. GlaxoSmithKline plc COMPANY PUBLICATION 2002 October 23
14. 478510 Product development pipeline. GlaxoSmithKline plc COMPANY PUBLICATION 2003 February 12
15. 3 receptor antagonism in conscious rats: Evidence to support a peripheral mechanism of action. Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L NEUROGASTROENTEROL MOTIL 2003 15 4 363-369
16. 515870 Drug development pipeline. GlaxoSmithKline plc COMPANY WORLDWIDE WEBSITE 2003 December 03
17. 516398 GlaxoSmithKline Research and Development day. GlaxoSmithKline plc COMPANY PRESENTATION 2003 December 03
18. 516472 Drug development update. GlaxoSmithKline plc COMPANY COMMUNICATION 2003 December 08
19. 529240 Annual Report 2003: GlaxoSmithKline. GlaxoSmithKline plc ANNUAL REPORT 2004 March 26
20. 3 receptor antagonist talnetant (SB-223412) modulates peristalsis induced by supra-optimal distension pressure in the guinea pig isolated ileum. Tuladhar, BR, Aziz E, Sanger GJ GASTROENTEROLOGY 2004 126 4 Suppl 2 Abs 1003
21. 572377 CNS pipeline presentation. GlaxoSmithKllne plc COMPANY PRESENTATION 2004 November 23
22. 3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Sanger GJ BR J PHARMACOL 2004 141 8 1303-1312
23. 583023 The search for novel antipsychotics: Pharmacological and molecular targets. Sanger DJ EXPERT OPIN THER TARGETS 2004 8 6 631-641
24. 595471 A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorders. Meltzer HY, Arvanitis L, Bauer D, Rein W AM J PSYCHIATRY 2004 161 6 975-984
25. 601819 Role of peripheral tachykinin receptors in neurogenic inflammation of the respiratory, genitourinary and gastrointestinal systems. Evangelista S, Patacchini R, Maggi CA CURR MED CHEM ANTI-INFLAMMATORY & ANTI-ALLERGY AGENTS 2003 2 157-174
26. 601959 Clinical trials: Phase II study of GlaxoSmithKline's talnetant in schizophrenia. INTERNET SITE 2005 May 17 http://www.clinicaltrials.gov
27. 601967 GSK psychiatry pipeline update: 597599, 372475, 649868 and talnetant. GlaxoSmithKline plc COMPANY PRESENTATION 2004 November 23
28. 602289 GSK psychiatry pipeline update: 353162, 597599, talnetant and 468816. GlaxoSmithKline plc COMPANY PRESENTATION 2003 December 03